Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 172.22M | 210.78M | 215.23M | 239.40M | 162.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 172.22M | 210.78M | 215.23M | 239.40M | 162.87M |
| Cost of Revenue | 128.77M | 125.31M | 120.19M | 111.13M | 105.39M |
| Gross Profit | 43.45M | 85.48M | 95.04M | 128.27M | 57.48M |
| SG&A Expenses | 39.34M | 38.47M | 37.26M | 34.82M | 33.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.11M | 163.77M | 157.45M | 145.94M | 139.14M |
| Operating Income | 4.11M | 47.01M | 57.78M | 93.45M | 23.73M |
| Income Before Tax | 23.81M | 66.49M | 76.42M | 110.38M | 40.51M |
| Income Tax Expenses | -972.00K | 859.00K | 21.47M | 5.93M | 17.02M |
| Earnings from Continuing Operations | 24.78 | 65.63 | 54.95 | 104.44 | 23.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.78M | 65.63M | 54.95M | 104.44M | 23.49M |
| EBIT | 4.11M | 47.01M | 57.78M | 93.45M | 23.73M |
| EBITDA | 7.89M | 50.78M | 61.30M | 96.87M | 26.97M |
| EPS Basic | 0.87 | 1.99 | 1.68 | 3.09 | 0.70 |
| Normalized Basic EPS | 0.54 | 1.27 | 1.46 | 2.04 | 0.76 |
| EPS Diluted | 0.80 | 1.90 | 1.59 | 2.96 | 0.63 |
| Normalized Diluted EPS | 0.50 | 1.22 | 1.40 | 1.97 | 0.72 |
| Average Basic Shares Outstanding | 156.73M | 149.15M | 141.68M | 134.33M | 133.31M |
| Average Diluted Shares Outstanding | 160.26M | 153.98M | 144.30M | 138.44M | 136.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |